Formula Pharmaceuticals has appointed Dr. Malcolm K. Brenner, founding director of the Center for Cell and Gene Therapy at Baylor College of Medicine, as a member of its Scientific Advisory Board (SAB). The SAB serves as a strategic resource to Formula as it continues to develop Chimeric Antigen Receptor (CAR) immunotherapies leveraging Cytokine Induced Killer (C.I.K.) cells targeting cancer and autoimmune disease.

“We are very excited to work with Dr. Malcolm Brenner, whose is a world leading expert in genetically modified T cells for cancer immunotherapy,” said Maurits W. Geerlings, President and CEO of Formula Pharmaceuticals. “Dr. Brenner’s invaluable insights in translational and molecular medicine will help us maximize the therapeutic potential within our C.I.K. CAR technology platform and drug candidates.”

Brenner will join fellow members of Formula’s SAB, Dr. David Scheinberg at Memorial Sloan-Kettering Cancer Center, Dr. Robert Negrin at Stanford University and Dr. Katy Rezvani at M.D. Anderson Cancer Center.

Brenner is a professor in the departments of Pediatrics and Medicine, Section of Hematology-Oncology at Baylor College of Medicine. He is also the founding director of the Center for Cell and Gene Therapy at Baylor College of Medicine, The Methodist Hospital and Texas Children’s Hospital.